CMIC Holdings Co., Ltd. said its affiliate, CMIC Co., Ltd., a contract research organization (CRO) in Japan, is providing monitoring services for Avigan Tablet (favipiravir), a product that Fujifilm Toyama Chemical Co., Ltd. gained approval in Japan for manufacture and sale as an influenza antiviral drug, phase III clinical trial in Japan and will support for manufacturing the product as a contract development and manufacturing organization (CDMO).
 
Recently, Fujifilm announced the start of clinical trials of Avigan in Japan and overseas as one of the drug candidates for COVID-19. In addition, the Japanese government plans to stockpile two million treatment courses of Avigan, as part of the Japanese government’s emergency economic package.
 
Also, CMIC CMO Co., Ltd., a CDMO in Japan, will manufacture Avigan Tablet at their main plant to contribute to Fujifilm’s accelerated production schedule.